Skip to main content
Clinical Trials/NCT03849820
NCT03849820
Terminated
Not Applicable

Open vs Robotic Assisted Partial Nephrectomy

Intuitive Surgical12 sites in 1 country247 target enrollmentMarch 12, 2019
ConditionsRenal Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Renal Cancer
Sponsor
Intuitive Surgical
Enrollment
247
Locations
12
Primary Endpoint
30 day complications
Status
Terminated
Last Updated
10 months ago

Overview

Brief Summary

To demonstrate that Robotic-Assisted partial nephrectomy is superior to Open partial nephrectomy in reducing the number of 30 day post-operative complications (Clavien-Dindo Type I-V) for patients with intermediate to high complexity kidney tumors.

Detailed Description

Partial nephrectomy is the surgical removal of a kidney tumor while unaffected tissue remains intact so that the kidney function is maintained as far as possible. The more radical procedure would be the complete removal of the kidney, which is not examined in this trial. Surgery will be randomized either to an open technique involving a large incision or the robotic assisted technique with a few small incisions (keyhole surgery). With robotic assisted surgery the movements of the surgeon are translated into the movement of the instruments. It is not clear which of the two procedures, open or robotic assisted, has less complications. It is expected that these are different due to the different level of invasiveness and the level of direct access to the organ. This study aims to show that robotic assisted surgery results in less complications than open surgery.

Registry
clinicaltrials.gov
Start Date
March 12, 2019
End Date
October 25, 2022
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or older
  • Patient with a renal tumor that is a candidate for OPEN surgery and robotic assisted surgery (RAS) partial nephrectomy (PN)
  • R.E.N.A.L. score ≥ 7
  • eGFR ≥ 50 ml/min/1.73 m²
  • Anticoagulation is accepted according to the surgeon's practice

Exclusion Criteria

  • Solitary kidney or functionally solitary kidney
  • Prior surgery at the affected kidney excluding endoscopic kidney stone surgery
  • Bilateral tumors
  • Multiple renal tumors requiring excision
  • Renal vein tumor thrombus
  • Likely insufficient volume of remaining parenchyma after partial nephrectomy to maintain viable kidney remnant
  • Metastatic disease with life expectancy of less than 1 year
  • Pregnancy or suspected pregnancy
  • Planned concomitant procedure
  • Subject who is unable or unwilling to comply with the protocol requirements

Outcomes

Primary Outcomes

30 day complications

Time Frame: Day of surgery to 30th post operative day

Any complication that occurred within 30 days post surgery

Secondary Outcomes

  • Ischemia time(Day of surgery)
  • Pain assessment(Baseline until Day 90)
  • Pain Medication(Baseline until Day 90)
  • Kidney function via the estimated glomerular filtration rate (eGRF)(Baseline until Day 5 / discharge (whatever is earlier))
  • Surgical radicality conversions(Day of surgery)
  • Overall survival(Day of surgery to 5 years)
  • Neuropathic pain(Baseline and Day 30 and Day 90)
  • Disease free survival(Day of surgery to 5 years)
  • Procedure related reoperations(Day 90)
  • Quality of recovery from the intervention(Baseline until Day 5 / discharge (whatever is earlier))
  • Operative time(Day of surgery)
  • Intraoperative blood loss(Day of surgery)
  • Post operative complications(Day 90)
  • Procedure related readmissions(Day 90)
  • Comprehensive Complication Index(Day of surgery to 30th post operative day)
  • Length of stay(Discharge)
  • Quality of life questionnaire, generic measure(Baseline until Day 90)
  • Quality of life questionnaire, cancer patient specific(Baseline until Day 90)
  • Disease specific survival(Day of surgery to 5 years)
  • Local recurrence free survival(Day of surgery to 5 years)

Study Sites (12)

Loading locations...

Similar Trials